Bioventix
OrganizationHeard in 2 episodes across 1 show since Mar 2026
A UK biotechnology company that develops and commercializes high-affinity antibodies used in diagnostic tests, particularly in clinical laboratories.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 1 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
| Nov 2026 | 0 |
Email alert
Email me when Bioventix comes up on a podcast
One email a week at most, with the new episodes that mention Bioventix. Free, no account needed, unsubscribe in one click.
What experts have said about Bioventix
4 statements · 1 positive · 3 negative
Bioventix’s share price has fallen sharply and persistently.
“I think most— Bioventix is another one that used to be such a quality growth stock, but the share price is just a 45-degree line downwards.”
Open the episode · Paul's Podcast - Fri 13 Mar 2026Listen at 32:53
Bioventix’s 10.5% dividend yield signals doubts about dividend sustainability.
“£75 million market cap, 10.5% dividend yield, which is saying to you the market doesn't think the dividends are sustainable.”
Open the episode · Paul's Podcast - Fri 13 Mar 2026Listen at 33:06
Bioventix’s 10.5% yield signals doubts about dividend sustainability.
“10.5% dividend yield, which is saying to you the market doesn't think the dividends are sustainable.”
Open the episode · Paul's Podcast - Fri 13 Mar 2026Listen at 33:09
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Bioventix, newest first